drugset / Trial / NCT01567930
Temsirolimus as Second-line Therapy in HCC
Phase 2
Unknown
25 enrolled
University of Tennessee Cancer Institute
Wyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the activity of temsirolimus in patients who have advanced hepatocellular carcinoma (HCC) and have been treated with one previous chemotherapy or biologic therapy like sorafenib, but have experienced disease progression or intolerance to that therapy.
Timeline
- Start
- 2010-02
- Primary completion
- 2012-12
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | — | Intravenous |